$Bionano Genomics(BNGO)$The company has met my expectations as an investor.
1) Data validation through publications and running of their own clinical trials for onco, haematological malignancies and pre/post natal testing. With good and reproducible data, the company can sell their machine to clinics and labs with lesser hiccups.
2) Acquisition of Lineagen and Biodiscovery also works to produce more robust data for use in clinical settings alongside NGS. This goes well with the partnerships in China for the clinical testing market.
3) There's still 200m in cash post acquisition, so the company can expand further.
4) I know that the FDA approval is not necessary, but I speculate that the company will edge towards it once the clinical trials are completed. Inertia and adoption friction is rampant in the healthcare industry, so the approval might be push that's needed to get labs and clinics to dump Karyotyping/CMA for next gen cytogenetics.
Patience is the key with bionano. I'm long till 2025.
精彩评论